Stavropoulos A, et al. - In patients who take antiresorptive drugs (ARDs) vs patients who don’t, experts evaluated the outcome and complication rate of implant therapy, including associated bone grafting procedures. In general, patients on ARDs do not lose more implants nor do they suffer more implant-related complications/ failures vs implant patients without BP intake. There is almost no information available on the possible effect of high-dose BPs or other widely used ARDs (e.g., denosumab), on implant therapy or on the success or safety of bone grafting procedures. Findings suggested considering patients with high-dose ARD intake for management of malignancies, patients on oral BP over a longer period of time, and patients with comorbidities as high-risk patients for medication-related osteonecrosis of the jaws (MRONJ). In short, implant therapy was not compromised by low-dose oral bisphosphonate (BP) intake for osteoporosis treatment.